Vertex acquired rights to Concert Pharmaceuticals’s cystic fibrosis drug CTP-656. The drug is a deuterated version of Vertex’s own compound ivacaftor, which it sells under the name Kalydeco.

CTP-656 Currently in Phase II clinical trials. The deal avoided a potential litigation between the two companies.

CTP-656

Links:

BioSpace: “Vertex (VRTX) Inks Deal Worth $250 Million for Concert Pharma (CNCE)’s Cystic Fibrosis Drug”

C&EN: “Vertex Buys Concert’s Cystic Fibrosis Drug”